CKDXF (Ceryvyn Therapeutics) Days Sales Outstanding: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ceryvyn Therapeutics Days Sales Outstanding?

Ceryvyn Therapeutics's average Accounts Receivable for the six months ended in Jun. 2026 was $0.00 Mil. Ceryvyn Therapeutics's Revenue for the six months ended in Jun. 2026 was $0.00 Mil.

The historical rank and industry rank for Ceryvyn Therapeutics's Days Sales Outstanding or its related term are showing as below:

CKDXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 673.32   Med: 1143.13   Max: 30042.31
Current: 30042.31

During the past 13 years, Ceryvyn Therapeutics's highest Days Sales Outstanding was 30042.31. The lowest was 673.32. And the median was 1143.13.

CKDXF's Days Sales Outstanding is ranked worse than
99.88% of 840 companies
in the Biotechnology industry
Industry Median: 69.01 vs CKDXF: 30042.31

Ceryvyn Therapeutics's Days Sales Outstanding stayed the same from Jun. 2025 () to Jun. 2026 ().

Ceryvyn Therapeutics  (OTCPK:CKDXF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Ceryvyn Therapeutics Days Sales Outstanding Related Terms

Ceryvyn Therapeutics Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Days Sales Outstanding Chart

Ceryvyn Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CKDXF vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Days Sales Outstanding falls into.


Ceryvyn Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Ceryvyn Therapeutics's Days Sales Outstanding for the fiscal year that ended in Jun. 2026 is calculated as

Days Sales Outstanding (A: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2025 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( ( + ) / 1 ) / 0.0006776229399978*365
=0 / 0.0006776229399978*365
=0.00

Ceryvyn Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding (Q: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2025 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( ( + ) / 1 ) / 0*365 / 2
=0 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.